Ethel Weld, MD

CRS:

JHU

Role:

Email:

eweld@jhmi.edu
  • Protocol chair, IMPAACT 2005
  • Protocol vice-chair, IMPAACT 2022
  • Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
  • Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
  • Member, Pharmacology Core, HPTN Laboratory Core
  • Member, TB in Pregnancy Working Group
  • Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More